Nurix Therapeutics (NASDAQ:NRIX – Get Free Report) and MediWound (NASDAQ:MDWD – Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, earnings, profitability and institutional ownership.
Profitability
This table compares Nurix Therapeutics and MediWound’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Nurix Therapeutics | -928.44% | -76.09% | -57.31% |
| MediWound | -170.10% | -47.24% | -24.27% |
Analyst Recommendations
This is a summary of recent ratings for Nurix Therapeutics and MediWound, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nurix Therapeutics | 1 | 1 | 13 | 0 | 2.80 |
| MediWound | 1 | 1 | 2 | 0 | 2.25 |
Institutional & Insider Ownership
46.8% of MediWound shares are owned by institutional investors. 6.7% of Nurix Therapeutics shares are owned by insiders. Comparatively, 9.2% of MediWound shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Valuation & Earnings
This table compares Nurix Therapeutics and MediWound”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Nurix Therapeutics | $83.98 million | 31.70 | -$264.46 million | ($3.45) | -7.43 |
| MediWound | $16.96 million | 10.35 | -$23.88 million | ($1.80) | -7.59 |
MediWound has lower revenue, but higher earnings than Nurix Therapeutics. MediWound is trading at a lower price-to-earnings ratio than Nurix Therapeutics, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Nurix Therapeutics has a beta of 1.8, indicating that its stock price is 80% more volatile than the S&P 500. Comparatively, MediWound has a beta of 0.14, indicating that its stock price is 86% less volatile than the S&P 500.
Summary
MediWound beats Nurix Therapeutics on 8 of the 14 factors compared between the two stocks.
About Nurix Therapeutics
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.
About MediWound
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
Receive News & Ratings for Nurix Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nurix Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
